What's Happening?
Combat Medical, a medical device company, has announced the successful raising of £2.6 million in the first close of a Series A financing round. This funding is aimed at advancing its hyperthermic intravesical chemotherapy treatment, HIVEC®, through phase
3 clinical trials and towards FDA registration. The investment round was led by the T&J Meyer Family Foundation, with participation from Varia Ventures, NW Angel Fund, and other non-institutional investors. The funds will support the ongoing pivotal FDA registration trial, HIVEC HEAT, which seeks to establish the efficacy of HIVEC as a safe and tolerable alternative to the current standard of care for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).
Why It's Important?
The funding is crucial for Combat Medical as it aims to change the standard of care for patients with BCG unresponsive NMIBC, a condition that currently requires radical cystectomy. The HIVEC treatment offers a bladder-sparing alternative, which could significantly improve patient outcomes and reduce the need for invasive surgeries. The successful completion of the FDA registration trial could lead to broader adoption of HIVEC, providing clinicians and payers with advanced, affordable treatment options. This development is particularly significant for the U.S. market, where the company plans to expand its clinical programs.
What's Next?
Combat Medical plans to use future financings to complete the FDA registration process and scale its operations. The company is also looking to expand its clinical programs for advanced bladder and peritoneal cancers, with a focus on entering the U.S. market. The successful completion of the phase 3 clinical trials and subsequent FDA approval could pave the way for the widespread adoption of HIVEC as a standard treatment for NMIBC.
